10-Q: REMSLEEP HOLDINGS, INC. Q2 2026 Financials Show Increased Net Loss

REMSLEEP HOLDINGS, INC. reported a net loss of $393,410 for the six months ended June 30, 2026, a significant increase from the prior year, alongside a going concern warning.

Summary

• For the six months ended June 30, 2026, REMSleep Holdings, Inc. reported a net loss of $393,410, an increase from $373,260 in the same period of 2025.
• Total assets decreased to $153,863 as of June 30, 2026, from $339,756 as of December 31, 2025.
• Total liabilities increased to $434,791 as of June 30, 2026, from $307,694 as of December 31, 2025.
• Shareholders' equity turned negative, reaching ($280,928) as of June 30, 2026, compared to $32,062 as of December 31, 2025.
• The company has a going concern warning due to accumulated losses and negative cash flow from operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses, a going concern warning, and a substantial increase in general and administrative expenses, despite some operational adjustments.

Positives

• The company has a patent for its Deltawave CPAP Pillows Mask (Utility patent 10987481 awarded April 27, 2021) and a design patent (D1,017,025 S awarded March 5, 2024).
• Lease expenses decreased by 75.1% due to a new, less expensive lease in a new location.
• Compensation expenses increased, indicating potential investment in personnel.
• The company is transitioning its business model towards e-commerce and e-retail sales channels.

Negatives

• Net loss increased by $307,922 for the six months ended June 30, 2026, compared to the same period in 2025.
• General and administrative expenses increased by 310.0% to $223,138 for the six months ended June 30, 2026.
• Total liabilities increased by $127,097 from December 31, 2025, to June 30, 2026.
• Shareholders' equity is negative ($280,928) as of June 30, 2026.
• The company has a going concern warning from its independent auditor.
• Cash used in operating activities was $418,377 for the six months ended June 30, 2026.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses and insufficient cash flow.
• Failure to generate sufficient revenues or raise additional capital could have a material adverse effect on the company and its shareholders.
• The company faces intense competition from substantially larger and better-capitalized competitors.
• The company's future success depends on its ability to secure, maintain, and enforce a strong intellectual property portfolio.
• Attracting additional capital sufficient to finance working capital requirements and investments in plant, property, and equipment is a significant challenge.

Future Outlook

The company aims to develop sleep products for the treatment of OSA and capture 10% of the market within the next 24 months. Management plans to seek additional capital through private placement and public offering of its common stock. The business model is transitioning towards e-commerce and e-retail sales channels.

Management Comments

• Management believes its DeltaWave product effectively addresses issues affecting patient compliance with CPAP treatment, such as comfort, breathing mechanics, and claustrophobia.
• The company's future success and viability are dependent upon its ability to generate capital financing.
• The company has implemented operational and administrative changes under new management, including relocating its principal office operations to Florida and establishing a new warehouse facility.

Industry Context

StockSavvy.ai notes that the sleep apnea market is competitive, with larger, better-capitalized players. REMSleep Holdings is attempting to differentiate through product innovation (DeltaWave) and a strategic shift towards e-commerce, which aligns with broader retail trends.

Comparison to Industry Standards

• The company's reported net loss of $393,410 for the six months ended June 30, 2026, and the ongoing 'going concern' warning are significant deviations from the financial stability expected of established players in the medical device industry.
• While specific industry benchmarks for early-stage sleep apnea device companies are not detailed, the substantial increase in G&A expenses (310%) and the negative shareholders' equity are concerning indicators when compared to companies with sustainable operations.
• Competitors like ResMed and Philips Respironics, major players in the sleep apnea market, consistently report profitability and significant revenue growth, highlighting the challenging competitive landscape REMSleep Holdings operates within.

Corporate Governance

Legal Proceedings

• None disclosed.

Stakeholder Impact

• Shareholders: Negative impact due to increased net loss, negative equity, and going concern warning, which could lead to dilution or further value erosion.
• Creditors: Increased liabilities and going concern status may raise concerns about repayment of convertible notes and other obligations.
• Employees: Potential uncertainty regarding job security given the company's financial precariousness and management transition.

Next Steps

• Continue to develop sleep products for the treatment of OSA.
• Transition business model to focus more heavily on Internet e-commerce and e-retail sales channels.
• Seek additional capital through private placement and public offering of common stock.
• Expand into nationwide and then international markets.

Key Dates

Recommendation

The significant increase in net loss, negative shareholders' equity, substantial rise in G&A expenses, and the explicit going concern warning from the auditor strongly suggest a deteriorating financial condition. The company's ability to continue operations is in doubt without significant additional financing, making it a high-risk investment.

Keywords

sleep apnea products, CPAP therapy, DeltaWave, financial statements, going concern, net loss, convertible notes, shareholders equity